Assessing Cardiovascular Risk to Guide Hypertension Diagnosis and Treatment
Key result
Among US adults with elevated SBP (120-139 mm Hg) and high CVD risk, only 27.0% of untreated and 21.9% of treated patients would have qualified for SPRINT, and even fewer for HOPE-3.
Population
Nonpregnant adults aged 20 to 79 years participating in the 2007-2012 National Health and Nutrition…
Design
Cross-sectional
Authors
Discussion
Loading...
Member takes
Implication
Many US adults with SBP 120-139 mm Hg fall outside SPRINT/HOPE-3 criteria; leaves open optimal management for this population.
Study Design
Type
Cross-Sectional (n=14,142)
Multicenter
Yes
Structured PICO
P
Population
14,142 nonpregnant US adults aged 20 to 79 years from the 2007-2012 NHANES, evaluated to assess cardiovascular risk and eligibility for blood pressure treatment trials.
O
Outcome
Number and characteristics of adults with SBP of 120 mm Hg or higher, including SPRINT and HOPE-3 eligibility, and estimated number who may have newly required treatment initiation or intensification if various trial or risk-based criteria were applied
Millions of US adults have elevated SBP and high CVD risk but would not have been eligible for SPRINT, suggesting clinicians should consider CVD risk alongside BP measurements for management.
Cite This Study
Návar et al. (2016) conducted a cross-sectional in Elevated systolic blood pressure (n=14,142). SPRINT and HOPE-3 trial eligibility criteria was evaluated on Number and characteristics of adults with SBP ≥120 mm Hg, including SPRINT and HOPE-3 eligibility. Among US adults with elevated SBP (120-139 mm Hg) and high CVD risk, only 27.0% of untreated and 21.9% of treated patients would have qualified for SPRINT, and even fewer for HOPE-3.